Govt suspends website promoting e-pharmas on Aarogya Setu after HC order

In view of the Centre's stand, Justice Navin Chawla disposed of the petition filed by South Chemists and Distributors Association

delhi, high court, delhi high court, delhi HC, HC,
The plea has said the website, is linked to the Aarogya Setu app in a highly illegal, arbitrary and discriminatory manner.
Press Trust of India New Delhi
3 min read Last Updated : Jun 17 2020 | 2:09 PM IST
The Centre has informed the Delhi High Court that it has suspended a website which was linked to the official mobile application Aarogya Setu and promoting sale of medicines through e-pharmacies.

The Centre's submission came on a plea seeking to de-link from Aarogya Setu mobile app, the website -- www.aarogyasetumitr.in -- as it was acting as a marketing tool for e-pharmacies only.

In view of the Centre's stand, Justice Navin Chawla disposed of the petition filed by South Chemists and Distributors Association. The order, passed on Tuesday, was made available on the court's website on Wednesday.

The Aarogya Setu application makes use of Bluetooth and GPS to alert users who may have encountered people who later test positive for the coronavirus.

During the hearing, Additional Solicitor General Maninder Acharya, representing the Centre, submitted that the operation of www.aarogyasetumitr.in has been suspended.

She further said that if at all the website is to be re-launched, the authorities shall keep in mind the issues raised by the petitioners in the petition.


The plea has said the website, is linked to the Aarogya Setu app in a highly illegal, arbitrary and discriminatory manner.

It has said that the homepage of the website states here are some essential healthcare services you can avail from the safety and comfort of your home and then lists only the e-pharmacies.

There is no mention that medicines can also be procured by the local pharmacy stores which operate offline. It is submitted that the respondents (authorities) cannot be allowed to mislead the users of a government developed and mandated mobile application to believe that the drugs for the treatment of Covid-19 or to contain the spread of the disease are available only through the e-pharmacies, said the plea, filed through senior advocate Sudhir Nandrajog and lawyers Amit Gupta and Mansi Kukreja.

The Centre had earlier opposed the plea and said these are extraordinary circumstances and the website has been developed for easy accessibility of medicines to Covid-19 patients.

The petition has said there is absolutely no basis for a government-owned platform be used to promote private commercial ventures.


It has sought direction to the Ministry of Electronics and IT, National Informatics Centre and Niti Aayog to take steps so that the name 'aarogya setu' or any identical/ deceptively similar name is not misused to sponsor the commercial interests of arbitrarily hand-picked entities. It has further sought to take steps for immediate closure of the website.

The has plea said the authorities have allowed government developed mobile application 'Aarogya setu', which has been launched with a salient feature of limiting the spread of Covid-19, to be used for the benefit of selected handpicked companies

The mobile application 'Aarogya setu' itself gives a link to website http://www.aarogyasetumitr.in/ which gives a wrong and misleading impression to a user that the website as well as the information made available on it is also government-mandated and approved, it has said.

It has claimed that the similarity in the names of the mobile application and the website is intentional and the website seeks to take advantage of the name and goodwill which has been generated by Aarogya setu, even though the website is not government-owned.

The plea has said the criteria for getting listed as a vendor on the website is that the entity should be an e-pharmacy, which is arbitrary, without any intelligible differentia, wholly illegal and discriminatory.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronaviruse-pharmaciesDelhi High Court

Next Story